Cliff Asness's NKTR Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 22,542 shares of Nektar Therapeutics (NKTR) worth $1.57 M, representing 0.00% of the portfolio. First purchased in 2025-Q2, this short-term holding has been held for 3 quarters.
Based on 13F filings, Cliff Asness has maintained this position in NKTR for several quarters, showing initial confidence in the investment. Largest addition occurred in Q2 2026, adding 22,542 shares. Largest reduction occurred in Q3 2025, reducing 427,867 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Nektar Therapeutics (NKTR) Holding Value Over Time
Track share changes against reported price movement
Quarterly Nektar Therapeutics (NKTR) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | +22,542 | New Buy | 22,542 | $69.81 |
| Q3 2025 | -427,867 | Sold Out | 0 | $0.00 |
| Q2 2025 | +427,867 | New Buy | 427,867 | $25.84 |
Cliff Asness's Nektar Therapeutics Investment FAQs
Cliff Asness first purchased Nektar Therapeutics (NKTR) in Q2 2025, acquiring 427,867 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Nektar Therapeutics (NKTR) for 3 quarters since Q2 2025.
Cliff Asness's largest addition to Nektar Therapeutics (NKTR) was in Q2 2025, adding 427,867 shares worth $11.06 M.
According to the latest 13F filing for Q2 2026, Cliff Asness's firm, Aqr Capital Management LLC, owns 22,542 shares of Nektar Therapeutics (NKTR), valued at approximately $1.57 M.
As of the Q2 2026 filing, Nektar Therapeutics (NKTR) represents approximately 0.00% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in Nektar Therapeutics (NKTR) was 427,867 shares, as reported at the end of Q2 2025.